This site is intended for Healthcare professionals only.

AARC Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients


AARC Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients

AARC Clinical Practice Guideline were released in July 2015 relating to Hospitalized Adult and Pediatric Patients without Cystic Fibrosis. These are clinical practise guidelines on Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients

The major recommendations of the guidelines are as follows

  1. Recombinant human dornase alfa should not be used in adults and children with non-cystic fibrosis bronchiectasis.
  2. Routine use of bronchodilators to aid in secretion clearance is not recommended.
  3. Routine use of aerosolized N-acetylcysteine to improve airway clearance is not recommended.

Adult and Pediatric Patients with Neuromuscular Disease, Respiratory Muscle Weakness, or Impaired Cough

Recommendation

The use of aerosolized agents to change sputum physical properties or improve airway clearance cannot be recommended for patients with neuromuscular disease or weakness due to insufficient evidence.

Postoperative Adult and Pediatric Patients

Recommendations

  1. Mucolytics cannot be recommended for use in the treatment of atelectasis due to insufficient evidence.
  2. Routine administration of bronchodilators to postoperative patients is not recommended.

 

 

For full Guideline click on the following link:

Artical Source: Strickland SL, Rubin BK, Haas CF, Volsko TA, Drescher GS, O’Malley CA. AARC Clinical Practice Guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. Respir Care. 2015 Jul;60(7):1071-7. [63 references]

Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted